Results 101 to 110 of about 94,294 (254)

Safety and efficacy of the therapy with CD4 + CD25highCD127‐T regulatory cells: When paediatric patient becomes adult

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1392-1402, February 2026.
Abstract Aim CD4 + CD25highCD127‐T regulatory cells (Tregs) remain a drug candidate for immunotherapy of type 1 diabetes. We completed three trials testing Tregs in recently diagnosed type 1 diabetes children. Here, we looked for long‐term safety and efficacy aspects important in the authorisation of this therapy.
Marta Bandura   +18 more
wiley   +1 more source

Immunomodulatory role of decidual prolactin on the human fetal membranes and placenta [PDF]

open access: gold, 2023
Pilar Flores‐Espinosa   +8 more
openalex   +1 more source

Biochemical and Physiological Effects of Galanin in Health and Disease

open access: yesThe FASEB Journal, Volume 40, Issue 2, 31 January 2026.
Galanin is a biologically active neuropeptide hormone that mediates its effects through three galanin receptors. Galanin signaling induces changes in glucose homeostasis amongst others and plays a dynamic role in the physiological health of many organ systems.
Patrick Mireles   +3 more
wiley   +1 more source

FRI0257 PROLACTIN AND DEHYDROEPIANDROSTERONE SULFATE IN WOMEN WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS OF RECENT ONSET VERSUS CHRONIC INACTIVE PATIENTS [PDF]

open access: bronze, 2019
Olga Vera‐Lastra   +3 more
openalex   +1 more source

Stress‐Induced Activation of Prolactin‐NR4A1‐Midkine Axis Exacerbates Skin Inflammation

open access: yesAdvanced Science, Volume 13, Issue 5, 27 January 2026.
Chronic psychological stress activates prolactin signaling to reprogram dermal fibroblasts into APCDD1+ inflammatory effectors via NR4A1, driving midkine secretion. This paracrine hub amplifies keratinocyte proliferation and immune recruitment, thus exacerbating skin inflammation.
Zhiguo Li   +18 more
wiley   +1 more source

Exploring Adjunctive Novel Therapeutic Approach of KarXT (Xanomeline‐Trospium Chloride) for Managing Psychotic Symptoms in Patients With Schizophrenia and Alzheimer's Disease

open access: yesBrain and Behavior, Volume 16, Issue 1, January 2026.
An overview of the mechanism of action, clinical trials, and classical findings of KarXT for the management of psychotic symptoms in patients with schizophrenia and alzheimer's disease. ABSTRACT Background Acute psychotic symptoms like delusions and hallucinations are of major concern while treating patients with schizophrenia and alzheimer's psychosis,
Ashir Kanwal   +7 more
wiley   +1 more source

Extrapituitary prolactin promotes generation of Eomes-positive helper T cells mediating neuroinflammation [PDF]

open access: bronze, 2019
Chenyang Zhang   +5 more
openalex   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

open access: yesClinical Pharmacology in Drug Development, Volume 15, Issue 1, January 2026.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy